Ann Pediatr Endocrinol Metab.  2014 Sep;19(3):122-126. 10.6065/apem.2014.19.3.122.

The treatment of Graves' disease in children and adolescents

• Lee HS
• Hwang JS

• KMID: 2134078
• DOI: http://doi.org/10.6065/apem.2014.19.3.122

Abstract

Graves' disease (GD) accounts for 10%-15% of thyroid disorders in children and adolescents. The use of antithyroid drugs as the initial treatment option in GD is well accepted. An average two years remission is achieved in about 30% of children treated with antithyroid drugs. However, the optimal treatment duration and the predictive marker of remission after antithyroid drug therapy are still controversial. Additionally, 131I therapy and surgery are considered the option for treatment in children and adolescents with GD. We review the treatment options for pediatric GD and the possible determinants of remission and relapse on antithyroid drug treatment in children and adolescents.

Keyword

Hyperthyroidism; Graves' disease; Antithyroid agents

MeSH Terms

Adolescent*
Antithyroid Agents
Child*
Drug Therapy
Graves Disease*
Humans
Hyperthyroidism
Recurrence
Thyroid Gland
Antithyroid Agents

Reference

1. Metso S, Jaatinen P, Salmi J. Graves' disease. N Engl J Med. 2008; 359:1408–1409. PMID: 18822460.

2. Cooper DS. Hyperthyroidism. Lancet. 2003; 362:459–468. PMID: 12927435.

3. Weetman AP. Graves' disease. N Engl J Med. 2000; 343:1236–1248. PMID: 11071676.

4. Dotsch J, Rascher W, Dorr HG. Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs. 2003; 5:95–102. PMID: 12529162.

5. Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 352:905–917. PMID: 15745981.

6. Wilson R, Buchanan L, Fraser WD, Jenkins C, Smith WE, Reglinski J, et al. Evidence for carbimazole as an antioxidant? Autoimmunity. 1998; 27:149–153. PMID: 9609132.

7. Weetman AP. How antithyroid drugs work in Graves' disease. Clin Endocrinol (Oxf). 1992; 37:317–318. PMID: 1282852.

8. Karras S, Memi E, Kintiraki E, Krassas GE. Pathogenesis of propylthiouracil-related hepatotoxicity in children: present concepts. J Pediatr Endocrinol Metab. 2012; 25:623–630. PMID: 23155684.

9. Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010; 95:3260–3267. PMID: 20427502.

10. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007; 92:2157–2162. PMID: 17389704.

11. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011; 21:593–646. PMID: 21510801.

12. Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother. 2003; 37:1100–1109. PMID: 12841824.

13. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid. 2004; 14:459–462. PMID: 15242574.

14. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med. 1990; 150:621–624. PMID: 2310281.

15. Muldoon BT, Mai VQ, Burch HB. Management of Graves' disease: an overview and comparison of clinical practice guidelines with actual practice trends. Endocrinol Metab Clin North Am. 2014; 43:495–516. PMID: 24891174.

16. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2010; (1):CD003420. PMID: 20091544.

17. Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2004; (2):CD003420. PMID: 15106202.

18. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008; 93:3817–3826. PMID: 18628515.

19. Glaser NS, Styne DM. Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics. 2008; 121:e481–e488. PMID: 18267979.

20. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997; 82:1719–1726. PMID: 9177370.

21. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985; 60:1019–1024. PMID: 2579967.

22. Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr. 2014; 164:1189–1194.e1. PMID: 24518168.

23. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twentyfive percent remission every two years. J Clin Endocrinol Metab. 1987; 64:1241–1245. PMID: 3571426.

24. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab. 2012; 97:110–119. PMID: 22031519.

25. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997; 7:755–760. PMID: 9349579.

26. Lee SH, Lee SY, Chung HR, Kim JH, Kim JH, Lee YA, et al. Remission rate and remission predictors of Graves disease in children and adolescents. Korean J Pediatr. 2009; 52:1021–1028.

27. Song SM, Youn JS, Ko JM, Cheon CK, Choi JH, Yoo HW. The natural history and prognostic factors of Graves' disease in Korean children and adolescents. Korean J Pediatr. 2010; 53:585–591.

28. Kim SM, Hwang JS. Remission predictors of Graves' disease in children. J Korean Soc Pediatr Endocrinol. 2010; 15:100–105.

29. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, et al. Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab. 1999; 12:537–541. PMID: 10417970.

30. Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. Endocr J. 2005; 52:505–510. PMID: 16284425.

31. Feldt-Rasmussen U, Schleusener H, Carayon P. Metaanalysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab. 1994; 78:98–102. PMID: 8288723.

32. Kamath C, Adlan MA, Premawardhana LD. The role of thyrotrophin receptor antibody assays in graves' disease. J Thyroid Res. 2012; 2012:525936. PMID: 22577596.

33. Kim WK, Ahn BH, Han HS. The clinical course and prognostic factors to medical treatment of Graves' disease in children and adolescents. Ann Pediatr Endocrinol Metab. 2012; 17:33–38.

34. Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev. 2008; (3):CD006294. PMID: 18646146.

35. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003; 111(4 Pt 1):745–749. PMID: 12671107.

36. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr. 2002; 141:99–103. PMID: 12091858.

37. Boice JD Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006; 295:1060–1062. PMID: 16507808.

38. Boice JD Jr. Radiation and thyroid cancer: what more can be learned? Acta Oncol. 1998; 37:321–324. PMID: 9743452.

39. Chao M, Jiawei X, Guoming W, Jianbin L, Wanxia L, Driedger A, et al. Radioiodine treatment for pediatric hyperthyroid Grave's disease. Eur J Pediatr. 2009; 168:1165–1169. PMID: 19421775.

40. Rivkees SA. The management of hyperthyroidism in children with emphasis on the use of radioactive iodine. Pediatr Endocrinol Rev. 2003; 1(Suppl 2):212–221. PMID: 16444161.

41. Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998; 83:3767–3776. PMID: 9814445.

42. Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med. 1988; 55:373–382. PMID: 2457461.

43. Rivkees SA. Pediatric Graves' disease: management in the post-propylthiouracil Era. Int J Pediatr Endocrinol. 2014; 2014:10. PMID: 25089127.

44. Clark JD, Gelfand MJ, Elgazzar AH. Iodine-131 therapy of hyperthyroidism in pediatric patients. J Nucl Med. 1995; 36:442–445. PMID: 7884506.

45. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab. 2007; 92:797–800. PMID: 17341574.

46. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf). 2008; 69:943–950. PMID: 18429949.

47. Sinha CK, Decoppi P, Pierro A, Brain C, Hindmarsh P, Butler G. Thyroid surgery in children: clinical outcomes. Eur J Pediatr Surg. 2014; 8. 21. [Epub]. http://dx.doi.org/10.1055/s-0034-1384649.

48. Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: a meta-analysis. J Surg Res. 2000; 90:161–165. PMID: 10792958.

49. Annerbo M, Stalberg P, Hellman P. Management of Grave's disease is improved by total thyroidectomy. World J Surg. 2012; 36:1943–1946. PMID: 22547016.